AusBiotech conference Brisbane 1 – 3 Nov 2023

Oculus BioMed Limited partners with The Centre for Eye Research Australia (CERA) in a deal to develop “SwitchGene” – Eye Gene therapies. 11 Oct 2023

October 9, 2023

Mr Roger McPherson appointed CFO / Company Secretary 27 Nov 2023

November 27, 2023

Published by admin on November 1, 2023

Tags

OBM recently attended Australias premier biotechnology conference in Brisbane – represented by CEO Andrew Coloretti & Non-Executive Director Michelle Gallaher. The conference included valuable one-on-one private meetings with industry executives and service providers. Importantly it was an opportunity to build brand awareness, network with delegates and exchange information about OBM.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

AusBiotech conference Brisbane 1 – 3 Nov 2023

Oculus BioMed Limited partners with The Centre for Eye Research Australia (CERA) in a deal to develop “SwitchGene” – Eye Gene therapies. 11 Oct 2023

Mr Roger McPherson appointed CFO / Company Secretary 27 Nov 2023

admin

Related posts

Data Indicate OBM’s OBM1701 Diffuses into the Retina and RPE and Effectively Alleviates Choroidal Neovascularisation in wet-AMD Animal Model after Topically Applied Has Been Published on An Association for Research in Vision and Ophthalmology (ARVO) Official Journal – 19th August 2025

Mr Roger McPherson appointed CFO / Company Secretary 27 Nov 2023

Oculus BioMed Limited partners with The Centre for Eye Research Australia (CERA) in a deal to develop “SwitchGene” – Eye Gene therapies. 11 Oct 2023

AusBiotech conference Brisbane
1 – 3 Nov 2023

Mr Roger McPherson appointed CFO / Company Secretary
27 Nov 2023

Oculus BioMed Limited partners with The Centre for Eye Research Australia (CERA) in a deal to develop “SwitchGene” – Eye Gene therapies.
11 Oct 2023